Stay Updated

Sign up to our newsletter to get the latest updates

Beckley Psytech appoints renowned psychedelic experts to Scientific Advisory Board

Beckley Psytech, the psychedelic medicine company, has appointed a series of respected figures from the psychiatric and psychedelic research fields to its Scientific Advisory Board, bringing decades of expertise to its research programme.

The new appointees include:

  1. Professor Guy Goodwin, Senior Research Fellow at the Department of Psychiatry, The University of Oxford
  2. Dr Robin L. Carhart-Harris PhD, Director of the Centre for Psychedelic Research at Imperial College London
  3. Professor Matthew W. Johnson PhD, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine
  4. Frederick Reinholdt MA, Senior Therapist in Psychedelics at The Institute of Psychiatry, Psychology and Neuroscience, King’s College London

Amanda Feilding, cofounder of Beckley Psytech and Chair of the Scientific Advisory Board, says: “The expansion of the Scientific Advisory Board adds further depth and resource to Beckley Psytech’s strong foundations in psychedelic medicinal research, and more momentum to our mission of bringing safe and effective pharmaceutical-standard psychedelic medicines to patients in need. “These appointments come at a pivotal time as we advance our lead programme on 5-MeO-DMT as well as expanding our research of other psychedelic agents, which we hope will offer transformative treatments for patients suffering from a variety of debilitating illnesses. We’re excited by the world-class knowledge, experience and strategic counsel the new Scientific Advisors bring to the Beckley team.”

Full biographies for the members of the Beckley Psytech Scientific Advisory Board can be found here.

For more information, please contact:

Anthony Cornwell/ Matt Jones/ Max Gibson

Four Communications

Tel: 020 3697 4200


Beckley Psytech:

Founded in 2019, Beckley Psytech is a for-profit company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. Our vision, supplemented by our partnership with the Beckley Foundation, is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients in need around the world suffering with these profoundly debilitating conditions.

More Like This

Company Announcements

Beckley Psytech raises £3m to develop ground-breaking psychedelic medicines

Beckley Psytech, the psychedelic medicine company, has raised £3m of Series A funding to develop a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases. Investors in the round includ... Read More

Company Announcements

Meet our new Scientific Advisory Board!

Renowned experts bring decades of experience to Beckley Psytech